14,740$
Echtzeit-Aktienkurs BELLUS Health Inc.
Bid:
Ask:
Echtzeit-Chart der BELLUS Health Inc. Aktie
Börsenkurse BELLUS Health Inc.
Fundamentaldaten der BELLUS Health Inc. Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2022 [CAD] | 0,02 Mio. | -99,61 Mio. | -99,05 Mio. | -0,86 | - | - | 89564,58 |
| 2021 [CAD] | 0,02 Mio. | -90,49 Mio. | -89,30 Mio. | -1,13 | - | - | 78176,25 |
| 2020 [CAD] | 0,02 Mio. | -43,28 Mio. | -42,60 Mio. | -0,72 | - | - | 57391,67 |
| 2019 [CAD] | 0,04 Mio. | -35,18 Mio. | -34,47 Mio. | -0,73 | - | - | 23322,33 |
| 2018 [CAD] | 0,04 Mio. | -9,74 Mio. | -9,08 Mio. | -0,27 | - | - | 18371,15 |
| 2017 [CAD] | 0,17 Mio. | -2,10 Mio. | -1,87 Mio. | -0,11 | - | - | 2965,31 |
| 2016 [CAD] | 1,89 Mio. | -2,36 Mio. | -2,16 Mio. | -0,14 | - | - | 132,08 |
| 2015 [CAD] | 4,02 Mio. | 0,09 Mio. | 0,20 Mio. | 0,02 | - | 982,67 | 48,26 |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der BELLUS Health Inc. Aktie
BELLUS Health is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. The lead program KIACTA™, a novel drug candidate, is in data review after announcing on June 20, 2016 top-line results from its Phase 3 study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTA™. KIACTA™ is also being developed as a treatment in a second indication called sarcoidosis, a rare, potentially fatal inflammatory condition that affects the lungs. An investigational new drug application (IND) for a Phase 2/3 clinical study is expected to be filed with the U.S. Food and Drug Administration in 2016. In addition, BELLUS Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS). sHUS often leads to dialysis, chronic kidne